ASO Author Reflections: Perspectives in the Measurement of Rapid Turnover Proteins in Patients with Hepatocellular Carcinoma

Annals of Surgical Oncology -     

Adjuvant Intraportal Venous Chemotherapy for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombi Following Hepatectomy Plus Portal Thrombectomy

Background The aim of this study was to evaluate the clinical value of adjuvant chemobiotherapy via portal vein for patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombi (PVTT) following hepatectomy plus thrombectomy. Methods Eighty-six HCC patients with tumor thrombi in the portal trunk and/or the first-order branch were divided into groups A (n = 33) and B (n = 53). Patients in group A were treated with hepatectomy plus portal thrombectomy in combination with postoperative adjuvant chemobiotherapy administered via portal vein. The chemobiotherapy regimen consisted of 5-FU, adriamycin, cisplatin, and IFNα. Patients in Group B were subjected to hepatectomy plus thrombectomy alone. Survival rates of the two groups were compared and prognostic factors were identified using Cox proportional hazards model. Results Group A had a significantly longer median tumor-free survival time and median survival time compared with group B, i.e., 5.1 vs. 2.5 months (p = 0.017) and 11.5 vs. 6.2 months (p = 0.007), respectively. One-, two-, and three-year tumor-free survival rates were remarkably higher in group A than in group B, i.e., 18.4% vs. 8.4%, 13.8% vs. 4.2%, and 9.2% vs. 4.2%, respectively. One-, two-, and three-year survival rates were markedly greater in group A than in group B, i.e., 46.8% vs. 23.4%, 14.4% vs. 5.8%, and 9.6% vs. 5.8%, respectively. Multivariate analysis using the Cox proportional hazards model revealed that adjuvant chemobiotherapy, pathologic grading, and tumor size were independent prognostic factors for survival time (p = 0.000, 0.001, and 0.013, respectively), and chemobiotherapy and pathologic grading were independent prognostic factors for tumor-free survival time (p = 0.002 and 0.003, respectively). Conclusions Surgical resection combined with adjuvant chemobiotherapy via portal vein is an effective and safe treatment modality for hepatocellular carcinoma with major portal vein thrombus.     

ASO Author Reflections: Future Perspectives of Novel Prognostic Predictor of Vessels that Encapsulate Tumor Cluster (VETC) for Hepatocellular Carcinoma

Annals of Surgical Oncology -     

Efficacy of a Hepatectomy and a Tumor Thrombectomy for Hepatocellular Carcinoma with Tumor Thrombus Extending to the Main Portal Vein

Introduction  

Hepatocellular carcinoma (HCC) with major portal tumor thrombus has been considered to be a fatal disease. A thrombectomy remains the only therapeutic option that offer a chance of complete tumor removal avoiding acute portal vein obstruction. However, the efficacy of tumor thrombectomy in addition to hepatectomy has not been well evaluated.     

Laparoscopic and Thoracoscopic Partial Hepatectomy for Hepatocellular Carcinoma

Several trials have been reported examining laparoscopic liver resections for the treatment of various kinds of liver tumors. However, there are no detailed reports on the use of laparoscopic (LH) and thoracoscopic (TH) hepatectomy for the treatment of hepatocellular carcinoma (HCC). Eleven laparoscopic and thoracoscopic partial liver resections were attempted for treating HCC. The indications for performing a laparoscopic or thoracoscopic partial hepatectomy were as follows: (1) the tumor was located on the surface of the liver; (2) the tumor was less than 3 cm in diameter; and (3) the tumor was not located adjacent to any large vessels. A TH was performed if the tumor was located in segment 8; an LH was performed if the tumor was located in segment 3, 4, or 5. Hand-assisted operations were performed in two patients. The mean operating time was 186.1 ± 44.0 minutes (range 130–310 minutes). The operative blood loss was 218.3 ± 197.6 ml (range 20–650 ml). The mean postoperative hospital stay was 11.3 ± 5.7 days (range 7–26 days). Two patients experienced postoperative complications (wound infection and ascites). No local recurrences have occurred to date. The overall 5-year survival rate and disease-free 5-year survival rate were 75.0% and 38.2%, respectively. Laparoscopic and thoracoscopic hepatic resections are less invasive than conventional surgical techniques and are useful for treating HCC in select patients.     

腹腔镜与开腹手术治疗肝细胞癌疗效的Meta分析

目的系统评价腹腔镜与开腹手术治疗肝细胞癌的疗效。方法计算机检索PubMed、中国期刊全文数据库、万方数据库、中国博硕士学位论文数据库及中国重要会议论文数据库2000～2011年发表的有关腹腔镜肝切除术和开腹肝切除术治疗肝细胞癌的相关文献,采用RevMan 5.0进行Meta分析。结果共纳入11项临床对照试验,包括781例患者,其中经腹腔镜手术治疗325例,开腹手术治疗456例。Meta分析结果显示,与开腹手术相比较,腹腔镜肝切除术能明显缩短手术时间〔加权均数差值（WMD）=-20.85,95%CI（-29.54,-12.16）,P〈0.000 01〕,减少术中出血量〔标准化均数差值（SMD）=-0.42,95%CI（-0.65,-0.19）,P=0.000 4〕,降低术后并发症发生率〔优势比（OR）=0.43,95%CI（0.28,0.65）,P〈0.000 1〕,缩短住院时间〔WMD=-4.32,95%CI（-6.29,-2.34）,P〈0.000 1〕。但术后复发率（P=0.80）和术后1年总生存率（P=0.98）、3年总生存率（P=0.41）、5年总生存率（P=0.12）以及1年无瘤生存率（P=0.15）、3年无瘤生存率（P=0.62）和5年无瘤生存率（P=0.99）差异均无统计学意义。结论对于病变位于CouinaudⅡ、Ⅲ、Ⅳ、Ⅴ及Ⅵ段,其直径小于5 cm,并且不影响第一和第二肝门血管的暴露,肝功能在Child B级以上的肝细胞癌患者,在条件允许的情况下可优先考虑腹腔镜肝切除术。     

Long-Term Results of Laparoscopic Hepatectomy Versus Open Hepatectomy for Hepatocellular Carcinoma: A Case-Matched Analysis

Background  

Laparoscopic hepatectomy (LH) is established as a safe and feasible treatment option for liver tumors. However, whether the adoption of laparoscopic approach for malignant tumors, such as hepatocellular carcinoma (HCC), will compromise the long-term result is still unknown. This study was designed to evaluate the long-term results of LH compared with a cohort of case-matched open hepatectomy (OH).     

腹腔镜与开腹肝切除术治疗肝癌的对比研究

目的探讨腹腔镜肝癌切除术的优越性。方法2012年1月～2013年12月,对原发性肝细胞肝癌行腹腔镜肝切除和开腹肝切除各22例,比较2组手术时间、术中出血量、术后排气时间、术后留置腹腔引流管时间、术后住院时间、手术费用、总费用、术后并发症。结果 与开腹手术相比,腹腔镜组术中出血量少[（75．5±43．2）mlVS．（203．5±61．4）ml,t=－8．000,P=0．000],手术时间短[（121．3±31．5）ｍinVS．（141．4±32．2）min,t=－2．093,P=0．042],排气早[（31．2±0．9）hVS．（39．8±0．8）h,t=－33．500,P=0．000],留置引流管时间短[（4．1±2．1）dVS．（6．4±1．9）d,t=－3．810,P=0．000],术后住院时间短[（9．1±4．4）dVS．（11．6±3．1）d,t=－2．179,P=0．035],但手术费用高[（6815．3±2113．4）元VS．（3732．2±618．4）元,t=6．567,P=0．000],2组并发症[1例V８．3例,ｘ２=0．275,P=0．600]和总费用[（14677．2±5444．3）元VS．（15123．3±4388．4）元,t=－0．299,P=0．766]差异无显著性。结论腹腔镜与开腹肝切除相比具有创伤小、痛苦少、术中出血少、术后恢复快、住院时间短等优越性。     

ASO Author Reflections: Reconsidering Resection for Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma

Annals of Surgical Oncology -     

ASO Author Reflections: Hilar Cholangiocarcinoma

Annals of Surgical Oncology -     

Extended Right Hepatectomy for Hepatocellular Carcinoma

Annals of Surgical Oncology -     

腹腔镜下非边缘部位小肝癌切除34例临床分析

目的探讨腹腔镜肝切除术在治疗非边缘部位小肝癌中的临床应用价值。方法对笔者所在医院2008年3月至2011年4月期间34例行腹腔镜肝切除术的非边缘部位小肝癌患者的临床资料进行回顾性分析。结果 34例患者中32例在不阻断肝血流情况下完成腹腔镜肝切除术,2例中转开腹。手术时间为(162±65)min(100～220 min),术中出血量为(295±166)ml(100～750 ml)。术后并发肝创面出血2例、腹水2例,无胆瘘、感染、CO2气栓等并发症发生,无围手术期死亡病例。术后住院时间为(6±2)d(4～9 d)。术后随访(23±7)个月(5～42个月),13例出现肝内非原位复发,术后1年生存率为90.6%(29/32),无瘤生存率为75.0%(24/32)。结论腹腔镜肝切除对部分非边缘部位小肝癌是一种安全有效的微创治疗方法,可考虑作为肝癌治疗的选择术式之一。     

R1 Hepatectomy With Exposure of Tumor Surface for Centrally Located Hepatocellular Carcinoma

Background

Hepatectomy with exposure of tumor surface (a special type of R1 resection) provides a chance of cure for selected patients with centrally located hepatocellular carcinoma (HCC) that is adherent to or compresses major vessels. However, the operative indications, safety, and patient outcomes are not well defined.

Methods

We performed hepatectomy for removal of complex centrally located HCC using a selective and dynamic region-specific vascular occlusion technique. Between May 2006 and March 2012, a total of 118 patients underwent resection with exposure of tumor surface (exposure group) and 169 underwent conventional hepatectomy (without exposure of the tumor and vascular surface). The short- and long-term outcomes of patients were evaluated and compared.

Results

The postoperative recovery of liver function was comparable between the two groups. Bile leakage occurred in five patients, all in the exposure group. The 1-, 3-, and 5-year recurrence-free survival rates were 74.4, 45.6, and 30.1 % in the exposure group and 80.9, 57.2, and 31.7 % in the control group (p = 0.041). Corresponding overall survival rates were 92.3, 70.3, and 44.9 % in the exposure group and 97.8, 81.4, and 53.1 % in the control group (p = 0.094).

Conclusions

Hepatectomy with exposure of tumor surface is technically demanding, but can be performed safely. It is also associated with a risk of tumor recurrence. Multidisciplinary combined therapy would be the solution and can contribute to improve overall survival.     

ASO Author Reflections: Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Annals of Surgical Oncology -     

Laparoscopic Extended Anterior Hepatic Sectionectomy with Right Hepatic Venous Tumor Thrombectomy (with Video)

Annals of Surgical Oncology -     

ASO Author Reflections: Clinical Implications of Circulating Tumor DNA in Pancreatic Cancer Patients

Annals of Surgical Oncology -     

ASO Author Reflections: 30 Years of Esophagectomy

Annals of Surgical Oncology -     

ASO Author Reflections: Long-Term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma

Annals of Surgical Oncology -